期刊
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 46, 期 5, 页码 468-474出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejps.2012.03.014
关键词
Argirein; Rhein; Pharmacokinetic; Bioavailability; HPLC; Rat
资金
- National Natural Science Foundation of China [81070145]
- National Key New Drug Innovation Program of China [2009ZX09308]
Aim: Rhein is an effective ingredient from Rheum palmatum L., Polygonum cuspidatum Sielb.et Zucc., Polygonum multiflorum Thunb. and has anti-inflammatory activity, however, plasma levels are too high and T-1/2 is not long enough following oral medication. Therefore, a modification of the rhein moiety was encouraged to improve the pharmacokinetic behavior. Argirein was produced by connecting rhein with L-arginine through hydrogen bond, which releases both rhein and L-arginine while getting into the body. The present study was to verify if the pharmacokinetic profile of argirein by measuring the released rhein is improved against those of untreated rhein administered alone. Methods: A reversed-phase HPLC with a mobile phase of methanol mixed with acetate buffer was conducted. Rhein was monitored after arginine administration by i.g. and i.v.. routes. Rhein alone was also administered and compared. Results: The C-max and AUC(0-48) of the released rhein following argirein medication were less than those following rhein administered. The bioavailability of argirein was 18.5-20.8% against 22.77-25.22% of rhein. A delayed T-max, a reduced C-max, and AUC(0-t), and an increased T-1/2 were significant in the argirein group as compared with those in the rhein group. Conclusion: The pharmacokinetic behavior of oral argirein presents a slow release property against those following oral rhein in rats. The released rhein following oral argirein is suitable in suppressing chronic inflammatory reactions attributed to prolonged T-1/2 and delayed Tmax due to its slow release pharmacokinetic characteristics. (C) 2012 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据